Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis

NCT06525311 is registered in ClinicalTrials.gov with Kowa Research Institute, Inc. as lead sponsor.

NCT NCT06525311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06525311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis
Lead sponsor
Kowa Research Institute, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2024
Completion date
April 9, 2025
Enrollment
17 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

compensated cirrhosis, primary biliary cholangitis